Clinically 0 10 0 10 O
significant 11 22 11 22 O
thrombocytopenia 23 39 23 39 B-chronic_disease

Currently 0 9 40 49 O
taking 10 16 50 56 O
edaravone 17 26 57 66 B-treatment
unless 27 33 67 73 O
after 34 39 74 79 O
completion 40 50 80 90 O
of 51 53 91 93 O
at 54 56 94 96 O
least 57 62 97 102 O
the 63 66 103 106 O
second 67 73 107 113 B-lower_bound
14 74 76 114 116 O
- 76 77 116 117 O
day 77 80 117 120 O
drug 81 85 121 125 O
- 85 86 125 126 O
treatment 86 95 126 135 O
period 96 102 136 142 O
, 102 103 142 143 O
as 104 106 144 146 O
long 107 111 147 151 O
as 112 114 152 154 O
Day 115 118 155 158 O
1 119 120 159 160 O
occurs 121 127 161 167 O
during 128 134 168 174 O
a 135 136 175 176 O
drug 137 141 177 181 O
- 141 142 181 182 O
free 142 146 182 186 O
period 147 153 187 193 O
at 154 156 194 196 O
least 157 162 197 202 O
24 163 165 203 205 B-lower_bound
hours 166 171 206 211 I-lower_bound
after 172 177 212 217 O
the 178 181 218 221 O
last 182 186 222 226 O
edaravone 187 196 227 236 O
dose 197 201 237 241 O
and 202 205 242 245 O
at 206 208 246 248 O
least 209 214 249 254 O
5 215 216 255 256 B-lower_bound
days 217 221 257 261 I-lower_bound
prior 222 227 262 267 I-lower_bound
to 228 230 268 270 O
the 231 234 271 274 O
first 235 240 275 280 O
dose 241 245 281 285 O
of 246 248 286 288 O
the 249 252 289 292 O
next 253 257 293 297 O
cycle 258 263 298 303 O

For 0 3 304 307 O
participants 4 16 308 320 O
participating 17 30 321 334 O
in 31 33 335 337 O
a 34 35 338 339 O
designated 36 46 340 350 O
drug 47 51 351 355 O
- 51 52 355 356 O
drug 52 56 356 360 O
interaction 57 68 361 372 O
( 69 70 373 374 O
DDI 70 73 374 377 O
) 73 74 377 378 O
cohort 75 81 379 385 O
in 82 84 386 388 O
the 85 88 389 392 O
MAD 89 92 393 396 O
stage 93 98 397 402 O
of 99 101 403 405 O
the 102 105 406 409 O
study 106 111 410 415 O
, 111 112 415 416 O
who 113 116 417 420 O
require 117 124 421 428 O
midazolam 125 134 429 438 B-treatment
/ 134 135 438 439 O
caffeine 135 143 439 447 O
administration 144 158 448 462 O
: 158 159 462 463 O
known 160 165 464 469 O
allergy 166 173 470 477 O
, 173 174 477 478 O
religious 175 184 479 488 O
prohibition 185 196 489 500 O
, 196 197 500 501 O
or 198 200 502 504 O
other 201 206 505 510 O
condition 207 216 511 520 O
limiting 217 225 521 529 O
midazolam 226 235 530 539 O
or 236 238 540 542 O
caffeine 239 247 543 551 O
administration 248 262 552 566 O

Positive 0 8 567 575 O
for 9 12 576 579 O
hepatitis 13 22 580 589 B-chronic_disease
C 23 24 590 591 I-chronic_disease
antibody 25 33 592 600 O
, 33 34 600 601 O
hepatitis 35 44 602 611 B-chronic_disease
B 45 46 612 613 I-chronic_disease
surface 47 54 614 621 O
antigen 55 62 622 629 O
, 62 63 629 630 O
or 64 66 631 633 O
human 67 72 634 639 B-chronic_disease
immunodeficiency 73 89 640 656 I-chronic_disease
virus 90 95 657 662 I-chronic_disease
( 96 97 663 664 I-chronic_disease
HIV 97 100 664 667 I-chronic_disease
) 100 101 667 668 I-chronic_disease
antibody 102 110 669 677 O

Upright 0 7 678 685 B-clinical_variable
forced 8 14 686 692 I-clinical_variable
vital 15 20 693 698 I-clinical_variable
capacity 21 29 699 707 I-clinical_variable
of 30 32 708 710 O
at 33 35 711 713 O
least 36 41 714 719 O
50 42 44 720 722 B-lower_bound
percent 45 52 723 730 I-lower_bound
( 53 54 731 732 I-lower_bound
% 54 55 732 733 I-lower_bound
) 55 56 733 734 I-lower_bound

